These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 22833573)

  • 21. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.
    Peasland A; Wang LZ; Rowling E; Kyle S; Chen T; Hopkins A; Cliby WA; Sarkaria J; Beale G; Edmondson RJ; Curtin NJ
    Br J Cancer; 2011 Jul; 105(3):372-81. PubMed ID: 21730979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olaparib-Resistant
    Biegała Ł; Gajek A; Marczak A; Rogalska A
    Cells; 2023 Mar; 12(7):. PubMed ID: 37048111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest.
    Madison DL; Stauffer D; Lundblad JR
    DNA Repair (Amst); 2011 Oct; 10(10):1003-13. PubMed ID: 21840268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.
    Bryant HE; Helleday T
    Nucleic Acids Res; 2006; 34(6):1685-91. PubMed ID: 16556909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mismatch repair-mediated cell cycle checkpoint response to fluorodeoxyuridine.
    Liu A; Yoshioka K; Salerno V; Hsieh P
    J Cell Biochem; 2008 Sep; 105(1):245-54. PubMed ID: 18543256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.
    Somnay Y; Lubner S; Gill H; Matsumura JB; Chen H
    Cancer Gene Ther; 2016 Oct; 23(10):348-354. PubMed ID: 27632933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarker-Guided Development of DNA Repair Inhibitors.
    Cleary JM; Aguirre AJ; Shapiro GI; D'Andrea AD
    Mol Cell; 2020 Jun; 78(6):1070-1085. PubMed ID: 32459988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells.
    Hsu HW; de Necochea-Campion R; Williams V; Duerksen-Hughes PJ; Simental AA; Ferris RL; Chen CS; Mirshahidi S
    Oral Oncol; 2014 Jul; 50(7):662-9. PubMed ID: 24735547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
    Murai J
    Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival.
    Wagner JM; Karnitz LM
    Mol Pharmacol; 2009 Jul; 76(1):208-14. PubMed ID: 19403702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer.
    Dey G; Bharti R; Braley C; Alluri R; Esakov E; Crean-Tate K; McCrae K; Joehlin-Price A; Rose PG; Lathia J; Gong Z; Reizes O
    J Ovarian Res; 2023 Jun; 16(1):122. PubMed ID: 37370140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition.
    Sakogawa K; Aoki Y; Misumi K; Hamai Y; Emi M; Hihara J; Shi L; Kono K; Horikoshi Y; Sun J; Ikura T; Okada M; Tashiro S
    Cancer Sci; 2013 Dec; 104(12):1593-9. PubMed ID: 24033642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ferulic acid in combination with PARP inhibitor sensitizes breast cancer cells as chemotherapeutic strategy.
    Choi YE; Park E
    Biochem Biophys Res Commun; 2015 Mar; 458(3):520-524. PubMed ID: 25677620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways.
    Liu X; Han EK; Anderson M; Shi Y; Semizarov D; Wang G; McGonigal T; Roberts L; Lasko L; Palma J; Zhu GD; Penning T; Rosenberg S; Giranda VL; Luo Y; Leverson J; Johnson EF; Shoemaker AR
    Mol Cancer Res; 2009 Oct; 7(10):1686-92. PubMed ID: 19825992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abrogation of ATR function preferentially augments cisplatin-induced cytotoxicity in PTEN-deficient breast cancer cells.
    Zhao JL; Yang J; Li K; Chen Y; Tang M; Zhu HL; Nie CL; Yuan Z; Zhao XY
    Chem Biol Interact; 2023 Nov; 385():110740. PubMed ID: 37802411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma.
    Weaver AN; Cooper TS; Rodriguez M; Trummell HQ; Bonner JA; Rosenthal EL; Yang ES
    Oncotarget; 2015 Sep; 6(29):26995-7007. PubMed ID: 26336991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
    Ha K; Fiskus W; Choi DS; Bhaskara S; Cerchietti L; Devaraj SG; Shah B; Sharma S; Chang JC; Melnick AM; Hiebert S; Bhalla KN
    Oncotarget; 2014 Jul; 5(14):5637-50. PubMed ID: 25026298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
    Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL
    Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair.
    Löser DA; Shibata A; Shibata AK; Woodbine LJ; Jeggo PA; Chalmers AJ
    Mol Cancer Ther; 2010 Jun; 9(6):1775-87. PubMed ID: 20530711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.